Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
  Home Print this page Email this page Small font sizeDefault font sizeIncrease font size Users Online: 652  

 
   Table of Contents      
ORIGINAL ARTICLE
Year : 2019  |  Volume : 18  |  Issue : 3  |  Page : 283-286

The effect of retinoic acid in the ability of cold solid thyroid nodule to take up radioactive iodine: A preliminary study


1 Department of Nuclear Medicine and Molecular Imaging, Faculty of Medicine, Dr. Hasan Sadikin General Hospital, Universitas Padjadjaran, Bandung, Indonesia
2 Department of Public Health, Universitas Padjadjaran, Bandung, Indonesia

Date of Submission08-May-2018
Date of Acceptance27-Jul-2018
Date of Web Publication9-Aug-2019

Correspondence Address:
Andreas Lim
Department of Nuclear Medicine and Molecular Imaging, Faculty of Medicine Universitas Padjadjaran, Dr. Hasan Sadikin General Hospital, Pasirkaliki 192, Bandung 40161, West Java
Indonesia
Login to access the Email id


DOI: 10.4103/wjnm.WJNM_48_18

Rights and Permissions
   Abstract 


One of the treatment options for benign thyroid nodules is radioactive iodine (RAI). However, this treatment is more effective for hot/warm solid thyroid nodules. Cold thyroid solid nodules are characterized by the lack of iodine uptake compared to normal thyroid tissue. Oral retinoic acid (RA) is a synthetic derivative of Vitamin A. The effect of RA on the uptake of RAI is still controversial. The aim of this study was to evaluate the effect of RA in the ability of a cold solid thyroid nodule to take up RAI. Individuals with a cold solid thyroid nodule based on ultrasonography and thyroid scintigraphy were included. Participants with liver dysfunction, smokers, and pregnant patients were excluded from the study. Each participant underwent thyroid uptake scintigraphy twice (pre- and post-RA consumption) using 35–37 MBq NaI-131. Participants consumed RA at a dose of 1 mg/kg body weight (BW) followed with 1.5 mg/kg BW. This study was approved by Dr. Hasan Sadikin General Hospital Ethic Committee. A total of 12 cold thyroid solid nodules were evaluated. The mean percentage of the nodule uptake value pre- and post-intervention was 1.11% and 0.62%, respectively (P = 0.004), while normal thyroid tissue uptake values pre- and post-intervention were 27.57% and 13.40%, respectively (P = 0.002). The percentage alteration of nodules and normal thyroid tissue uptake value were 42.4% and 51.5% lower, respectively (P = 0.354). This study showed that RA reduces the ability of cold solid thyroid nodule, as well as normal thyroid tissue, to take up RAI.

Keywords: Cold solid thyroid nodule, radioactive iodine therapy, retinoic acid


How to cite this article:
Lim A, Budiawan H, Darmawan B, Hidayat B, Sukandar H, Sundawa Kartamihardja AH. The effect of retinoic acid in the ability of cold solid thyroid nodule to take up radioactive iodine: A preliminary study. World J Nucl Med 2019;18:283-6

How to cite this URL:
Lim A, Budiawan H, Darmawan B, Hidayat B, Sukandar H, Sundawa Kartamihardja AH. The effect of retinoic acid in the ability of cold solid thyroid nodule to take up radioactive iodine: A preliminary study. World J Nucl Med [serial online] 2019 [cited 2019 Aug 23];18:283-6. Available from: http://www.wjnm.org/text.asp?2019/18/3/283/264154




   Introduction Top


Nodules in the thyroid gland, whether solitary or multiple, are very common in clinical practice. According to several epidemiologic studies, there is approximately 5% prevalence in women and 1% in men who live in iodine-sufficient parts of the world.[1],[2] Radioactive iodine (RAI) (NaI-131) has been used for over 50 years to treat clinical or subclinical hyperthyroidism due to Graves' disease or autonomously functioning thyroid nodules (either toxic or nontoxic).[3] The sodium iodide (Na +/I -) symporter (NIS), which was identified in 1996, is responsible for active iodine trapping to the thyroid follicular cell.[4] Cold thyroid nodules (CTNs) are characterized as nodules with less iodide uptake than normal thyroid tissue.[5] NIS expression in cold nodules is similar to nonnodular tissue due to TSH. Hot nodules have about 1.5 fold NIS expression compared to CTNs.[6],[7]

Oral retinoic acid (RA) is a synthetic derivative of Vitamin A. It is an important regulator of a diverse spectrum of physiological processes, including cell proliferation, differentiation, morphogenesis, angiogenesis, and apoptosis.[8] RA can induce several re-differentiating effects such as induction of 5'-deiodinase (D1)[9],[10] and increased expression of NIS mRNA.[11] In 2009, Handkiewicz-Junak et al. showed that RA increased RAI uptake in thyroid tissue in 17% of the 53 epithelial cell thyroid carcinoma patients studied, whose previous posttherapeutic I-131 scans were negative.[12] However, Schmutzler et al. showed that RA suppresses NIS expressions in normal thyroid tissue.[11]

The aim of this study is to evaluate the effect of RA to the uptake value of RAI in cold solid thyroid nodule.


   Materials and Methods Top


Subject

Between September 2017 and November 2017, a total of 10 patients were included in this study. Two participants were dropped off due to side effects of RA. Patients' characteristics are summarized in [Table 1].
Table 1: Patient characteristics

Click here to view


Inclusion criteria

Individuals with solid thyroid nodule based on ultrasonographic examination were evaluated for the thyroid nodule characteristics. Individuals with cold nodule were included in this study.

Exclusion criteria

Individuals with liver dysfunction, smokers, and pregnancy patients were excluded from this study.

Thyroid nodule characteristic determination

To determine the characteristic of the thyroid nodule, each participant underwent thyroid scintigraphy. A 1 mCi (37 MBq) of NaI-131 was administered orally, and 24 h later, the thyroid scintigraphy was performed.

Retinoic acid administration

A 1 mg/kg body weight (BW) of RA was taken by the participants for 2 weeks, followed by a 1.5 mg/kg BW for 4 weeks. Liver function test was performed before consuming RA and also 2 and 6 weeks after consuming.

Thyroid uptake calculation

The baseline uptake imaging values of the thyroid gland and nodule were collected before consuming RA. The imaging was performed at 24 h after administration of 1 mCi (37 MBq) of NaI-131. And 6 weeks after consuming RA, another uptake was repeated.

The uptake was calculated using the following formula:[13]



  • Pthyroid: decay-corrected total thyroid counts
  • Pbackground: decay-corrected background counts
  • Precount: decay-corrected counts of the preinjection syringe image
  • Postcount: decay-corrected counts of the postinjection syringe image.


Decay correction is calculated by multiplying the image counts by the factor as follows:

exp = (−0.693t)/T1/2

where

t: the time that elapses between preparation of the radiopharmaceutical and image acquisition

T1/2: half-life time of the tracer

A standard syringe was used to determine the exact t value.

Statistical analysis

A Wilcoxon test was used to analyze sample distribution. Unpaired t-test was used to analyze the significance of the alteration in the uptake value of the nodules and normal thyroid tissues. P <0.05 was considered statistically significant.


   Results Top


A total of 12 cold solid thyroid nodules from eight participants were evaluated. The mean percentage values of the nodule uptake pre- and post-intervention were 1.11% and 0.62% with a median of 0.65% and 0.32%, respectively (P = 0.004). The mean percentage uptake value of the normal thyroid tissue was 27.57% in preinterventional evaluation and 13.40% in postinterventional evaluation with a median of 28.42% and 14.45%, respectively (P = 0.002) [Figure 1].
Figure 1: Comparison of the normal thyroid tissue and cold thyroid nodule to take up NaI-131 pre- and post-intervention

Click here to view


The mean alteration percentage uptake of the nodules and the normal thyroid tissues were 42.4% and 51.5% with a median of 35.4% and 50.8%, respectively,

(P = 0.354). The comparison of the uptake values pre- and post-intervention is shown in [Table 2].
Table 2: Comparison of the uptake values pre- and post-intervention

Click here to view



   Discussion Top


Thyroid nodules can be detected in <5% of individuals screened by cervical palpation, but autopsy data have shown a 50% prevalence of nodular lesions in clinically normal thyroid glands.[1],[2],[14] According to a recent study (1999–2002), the use of ultrasonography by endocrinologists in the management of thyroid disease is increasing.[15],[16],[17],[18] That trend makes the unexpected detection of nonpalpable thyroid nodules <10–15 mm in diameter more frequent in clinical practice.[19] Most of these nodules are benign, at most only 5% were found to be malignant.[20] The first step in the management of a patient with nodular thyroid disease is to exclude the presence of malignancy. There are several approaches that can be applied to benign thyroid nodules such as surgery, iodine supplementation, levothyroxine, RAI (NaI-131), percutaneous ethanol injection, and percutaneous laser ablation.[21]

RAI has been used for over 50 years to treat clinical or subclinical hyperthyroidism due to Graves' disease or autonomously functioning thyroid nodules (either toxic or nontoxic).[3] The effectiveness of RAI in reducing the size of the thyroid gland is widely recognized.[22],[23] Uptake of RAI may be reduced in patients with multinodular goiters, especially the nontoxic forms, so in these cases, higher doses of RAI should be given.[21] The risk of hypothyroidism is approximately 10% after 5 years and unrelated to RAI dose.[24]

The NIS, which was identified in 1996, is responsible for active iodine trapping to the thyroid follicular cell.[4] High level of NIS in benign thyroid nodule may be taken as one of the indicators of the success of RAI therapy in decreasing nodular size. The highest NIS expression is in hot nodules, followed by warm nodules and then cold nodules. In cold nodules, NIS expression is similar to the surrounding nonnodular tissue.[7]

RA is a biologically active metabolite of Vitamin A. It is essential for morphogenesis, differentiation, and homeostasis.[25],[26] It is an effective therapeutic and chemopreventive agent for treating several cancers.[27],[28],[29] RA regulates thyroid-specific differentiation markers, such as type I D1, thyroperoxidase, and NIS.[30] In 1997, Schmutzler et al. showed that RA suppresses the expression of NIS in the normal thyroid cell line FRTL-5.[11]

This study showed a mean of 42.4% decrease in the capability of the nodule to take up RAI after administration of RA and also 51.5% decrease in the normal thyroid tissue.

Nygaard et al. found that hypothyroidism occurred in 6%–20% (P < 0.005) of 130 multinodular toxic goiter patients after a median of 42 months (range: 3–60 months) and within 5 years of treatment, the hypothyroidism frequency was 14%,[23] while Adamali et al. found that in toxic nodular goiter group, hypothyroidism occurred in 22.7% of the patients (P < 0.001).[31]

From this study, it was observed that the RAI uptake in the surrounding normal thyroid tissue was decreased more than the uptake in the nodule. It may be postulated that the use of RA will be useful in the RAI therapy for functional nodule in reducing the incidence of hypothyroidism. A further study with larger population with functional nodule is required to confirm the result of this study.


   Conclusion Top


This study showed that RA reduces the ability of cold solid thyroid nodule, as well as normal thyroid tissue, to take up RAI.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
   References Top

1.
Tunbridge WM, Evered DC, Hall R, Appleton D, Brewis M, Clark F, et al. The spectrum of thyroid disease in a community: The Whickham survey. Clin Endocrinol (Oxf) 1977;7:481-93.  Back to cited text no. 1
    
2.
Vander JB, Gaston EA, Dawber TR. The significance of nontoxic thyroid nodules. Final report of a 15-year study of the incidence of thyroid malignancy. Ann Intern Med 1968;69:537-40.  Back to cited text no. 2
    
3.
Chapman EM. History of the discovery and early use of radioactive iodine. JAMA 1983;250:2042-4.  Back to cited text no. 3
    
4.
Ajjan RA, Kamaruddin NA, Crisp M, Watson PF, Ludgate M, Weetman AP, et al. Regulation and tissue distribution of the human sodium iodide symporter gene. Clin Endocrinol (Oxf) 1998;49:517-23.  Back to cited text no. 4
    
5.
Cavalieri RR, McDouglas IR.In vitro isotopic tests and imaging. In: Braverman LE, Utiger R, editors. Werner and Ingbar's The Thyroid: A Fundamental and Clinical Text. Philadelphia: Lippincott-Raven; 1996. p. 902-9.  Back to cited text no. 5
    
6.
Russo D, Bulotta S, Bruno R, Arturi F, Giannasio P, Derwahl M, et al. Sodium/iodide symporter (NIS) and pendrin are expressed differently in hot and cold nodules of thyroid toxic multinodular goiter. Eur J Endocrinol 2001;145:591-7.  Back to cited text no. 6
    
7.
Syrenicz A, Wolny M, Kram A, Sworczak K, Syrenicz M, Garanty-Bogacka B, et al. Analysis of the sodium iodide symporter expression in histological slides from a nodular goiter. Arch Med Res 2007;38:219-26.  Back to cited text no. 7
    
8.
Damle N, Patnecha M, Kumar P, Maharjan S, Bal C. Retinoic acid therapy in patients with radioiodine negative differentiated thyroid cancer and clinical or biochemical evidence of disease: An initial experience. Indian J Nucl Med 2011;26:144-8.  Back to cited text no. 8
[PUBMED]  [Full text]  
9.
Van Herle AJ, Agatep ML, Padua DN 3rd, Totanes TL, Canlapan DV, Van Herle HM, et al. Effects of 13 cis-retinoic acid on growth and differentiation of human follicular carcinoma cells (UCLA R0 82 W-1) in vitro. J Clin Endocrinol Metab 1990;71:755-63.  Back to cited text no. 9
    
10.
Schreck R, Schnieders F, Schmutzler C, Köhrle J. Retinoids stimulate type I iodothyronine 5'-deiodinase activity in human follicular thyroid carcinoma cell lines. J Clin Endocrinol Metab 1994;79:791-8.  Back to cited text no. 10
    
11.
Schmutzler C, Winzer R, Meissner-Weigl J, Köhrle J. Retinoic acid increases sodium/iodide symporter mRNA levels in human thyroid cancer cell lines and suppresses expression of functional symporter in nontransformed FRTL-5 rat thyroid cells. Biochem Biophys Res Commun 1997;240:832-8.  Back to cited text no. 11
    
12.
Handkiewicz-Junak D, Roskosz J, Hasse-Lazar K, Szpak-Ulczok S, Puch Z, Kukulska A, et al. 13-cis-retinoic acid re-differentiation therapy and recombinant human thyrotropin-aided radioiodine treatment of non-functional metastatic thyroid cancer: A single-center, 53-patient phase 2 study. Thyroid Res 2009;2:8.  Back to cited text no. 12
    
13.
Becker D, Charkes ND, Dworkin H, Hurley J, McDougall IR, Price D, et al. Procedure guideline for thyroid uptake measurement: 1.0. Society of nuclear medicine. J Nucl Med 1996;37:1266-8.  Back to cited text no. 13
    
14.
Mortensen JD, Woolner LB, Bennett WA. Gross and microscopic findings in clinically normal thyroid glands. J Clin Endocrinol Metab 1955;15:1270-80.  Back to cited text no. 14
    
15.
Bennedbaek FN, Perrild H, Hegedüs L. Diagnosis and treatment of the solitary thyroid nodule. Results of a European survey. Clin Endocrinol (Oxf) 1999;50:357-63.  Back to cited text no. 15
    
16.
Bennedbaek FN, Hegedüs L. Management of the solitary thyroid nodule: Results of a North American survey. J Clin Endocrinol Metab 2000;85:2493-8.  Back to cited text no. 16
    
17.
Bonnema SJ, Bennedbaek FN, Wiersinga WM, Hegedüs L. Management of the nontoxic multinodular goitre: A European questionnaire study. Clin Endocrinol (Oxf) 2000;53:5-12.  Back to cited text no. 17
    
18.
Bonnema SJ, Bennedbaek FN, Ladenson PW, Hegedüs L. Management of the nontoxic multinodular goiter: A North American survey. J Clin Endocrinol Metab 2002;87:112-7.  Back to cited text no. 18
    
19.
Ross DS. Nonpalpable thyroid nodules – managing an epidemic. J Clin Endocrinol Metab 2002;87:1938-40.  Back to cited text no. 19
    
20.
Hegedüs L, Bonnema SJ, Bennedbaek FN. Management of simple nodular goiter: Current status and future perspectives. Endocr Rev 2003;24:102-32.  Back to cited text no. 20
    
21.
Filetti S, Durante C, Torlontano M. Nonsurgical approaches to the management of thyroid nodules. Nat Clin Pract Endocrinol Metab 2006;2:384-94.  Back to cited text no. 21
    
22.
Nygaard B, Hegedüs L, Nielsen KG, Ulriksen P, Hansen JM. Long-term effect of radioactive iodine on thyroid function and size in patients with solitary autonomously functioning toxic thyroid nodules. Clin Endocrinol (Oxf) 1999;50:197-202.  Back to cited text no. 22
    
23.
Nygaard B, Hegedüs L, Ulriksen P, Nielsen KG, Hansen JM. Radioiodine therapy for multinodular toxic goiter. Arch Intern Med 1999;159:1364-8.  Back to cited text no. 23
    
24.
Weetman AP. Radioiodine treatment for benign thyroid diseases. Clin Endocrinol (Oxf) 2007;66:757-64.  Back to cited text no. 24
    
25.
Giguère V. Retinoic acid receptors and cellular retinoid binding proteins: Complex interplay in retinoid signaling. Endocr Rev 1994;15:61-79.  Back to cited text no. 25
    
26.
Ross SA, McCaffery PJ, Drager UC, De Luca LM. Retinoids in embryonal development. Physiol Rev 2000;80:1021-54.  Back to cited text no. 26
    
27.
Lippman SM, Meyskens FL Jr. Treatment of advanced squamous cell carcinoma of the skin with isotretinoin. Ann Intern Med 1987;107:499-502.  Back to cited text no. 27
    
28.
Li G, Walch E, Yang X, Lippman SM, Clifford JL. Cloning and characterization of the human retinoid X receptor alpha gene: Conservation of structure with the mouse homolog. Biochem Biophys Res Commun 2000;269:54-7.  Back to cited text no. 28
    
29.
Saade M, Debahy NE, Houjeily S. Clinical remission of xeroderma pigmentosum-associated squamous cell carcinoma with isotretinoin and chemotherapy: Case report. J Chemother 1999;11:313-7.  Back to cited text no. 29
    
30.
Silva AC, Marassi MP, Mühlbauer M, Lourenço AL, Carvalho DP, Ferreira AC, et al. Retinoic acid effects on thyroid function of female rats. Life Sci 2009;84:673-7.  Back to cited text no. 30
    
31.
Adamali HI, Gibney J, O'Shea D, Casey M, McKenna TJ. The occurrence of hypothyroidism following radioactive iodine treatment of toxic nodular goiter is related to the TSH level. Ir J Med Sci 2007;176:199-203.  Back to cited text no. 31
    


    Figures

  [Figure 1]
 
 
    Tables

  [Table 1], [Table 2]



 

Top
 
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
    Abstract
   Introduction
    Materials and Me...
   Results
   Discussion
   Conclusion
    References
    Article Figures
    Article Tables

 Article Access Statistics
    Viewed27    
    Printed1    
    Emailed0    
    PDF Downloaded9    
    Comments [Add]    

Recommend this journal